Surgical oncology

Breast Lesion Localization Methods Market Worth 5750.9 Thousands of Procedures by 2025 - Exclusive Report by MarketsandMarkets™

Thursday, July 16, 2020 - 4:30pm

The overall market for breast lesion localization methods market is expected to grow rapidly owing to the increasing number of breast cancer surgeries and increasing awareness on early detection of breast cancer.

Key Points: 
  • The overall market for breast lesion localization methods market is expected to grow rapidly owing to the increasing number of breast cancer surgeries and increasing awareness on early detection of breast cancer.
  • Based on type, the breast lesion localization methods market is divided into wire localization, isotope localization, magnetic localization, electromagnetic localization, and others.
  • The wire localization segment accounted for the largest share of the breast lesion localization methods market in 2019.
  • By usage, the breast lesion localization methods market is segmented into tumor identification and sentinel lymph node identification.The sentinel lymph node identification segment is further divided by types of surgery into lumpectomy and mastectomy.The sentinel lymph node identification segment dominated thebreast lesion localization methods market in 2019.

Breast Lesion Localization Methods Market Worth 5750.9 Thousands of Procedures by 2025 - Exclusive Report by MarketsandMarkets™

Thursday, July 16, 2020 - 4:30pm

The overall market for breast lesion localization methods market is expected to grow rapidly owing to the increasing number of breast cancer surgeries and increasing awareness on early detection of breast cancer.

Key Points: 
  • The overall market for breast lesion localization methods market is expected to grow rapidly owing to the increasing number of breast cancer surgeries and increasing awareness on early detection of breast cancer.
  • Based on type, the breast lesion localization methods market is divided into wire localization, isotope localization, magnetic localization, electromagnetic localization, and others.
  • The wire localization segment accounted for the largest share of the breast lesion localization methods market in 2019.
  • By usage, the breast lesion localization methods market is segmented into tumor identification and sentinel lymph node identification.The sentinel lymph node identification segment is further divided by types of surgery into lumpectomy and mastectomy.The sentinel lymph node identification segment dominated thebreast lesion localization methods market in 2019.

Outlook on the Global Market for Radiofrequency Ablation Devices to 2027 - Featuring Baren-Boym, Covidien & ZenoMed Among Others

Wednesday, July 1, 2020 - 4:00pm

DUBLIN, July 1, 2020 /PRNewswire/ -- The "Radiofrequency Ablation Devices - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 1, 2020 /PRNewswire/ -- The "Radiofrequency Ablation Devices - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.
  • The Global Radiofrequency Ablation Devices market accounted for $3.12 billion in 2019 and is expected to reach $8.67 billion by 2027 growing at a CAGR of 13.6% during the forecast period.
  • Some of the key factors propelling market growth are increasing geriatric population, rising occurrence of chronic disorders, and improving healthcare infrastructure.
  • Some of the key players in Radiofrequency Ablation Devices Market include Stryker Corporation, Medtronic, Baren-Boym, Covidien, ZenoMed, AngioDynamics, Huaian Aofu Surgical Instruments Co Ltd, AtriCure Inc, MedSphere, and Ethicon.

Global Radiofrequency Ablation Devices Industry to 2027 - Key Drivers, Restraints, Opportunities & Threats - ResearchAndMarkets.com

Wednesday, June 24, 2020 - 1:10pm

The "Radiofrequency Ablation Devices - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Radiofrequency Ablation Devices - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.
  • The Global Radiofrequency Ablation Devices market accounted for $3.12 billion in 2019 and is expected to reach $8.67 billion by 2027 growing at a CAGR of 13.6% during the forecast period.
  • Some of the key factors propelling market growth are increasing geriatric population, rising occurrence of chronic disorders, and improving healthcare infrastructure.
  • Radiofrequency ablation is a minimally invasive procedure, suitable for patients with cardiac diseases, cancer and pain management.

Orca Bio Emerges With Nearly $300 Million to Transform Allogeneic Cell Therapy

Wednesday, June 17, 2020 - 12:00pm

Orca Bios $192 million Series D financing was co-led by Lightspeed Venture Partners and an undisclosed investor.

Key Points: 
  • Orca Bios $192 million Series D financing was co-led by Lightspeed Venture Partners and an undisclosed investor.
  • These proprietary mixtures have the potential to revolutionize allogeneic cell therapy for hematological and other cancers, as well as many other diseases and disorders.
  • While a conventional bone marrow transplant administers an uncontrolled cell product, Orca Bio has been the first to deliver a high precision cell therapy.
  • I look forward to the Orca Bio teams continued development and commercialization of revolutionary allogeneic cell therapies.

FDA and Health Canada Approve Thermedical’s Degassed Saline to Help Reduce Risk of Stroke

Tuesday, June 16, 2020 - 2:09pm

Health Canada and the U.S. Food & Drug Administration (FDA) approved Thermedicals degassed saline for use with its Saline Enhanced Radiofrequency (SERF) Ablation system and Durablate catheter , currently being studied for the treatment of ventricular tachycardia (VT), a leading cause of sudden cardiac death worldwide.

Key Points: 
  • Health Canada and the U.S. Food & Drug Administration (FDA) approved Thermedicals degassed saline for use with its Saline Enhanced Radiofrequency (SERF) Ablation system and Durablate catheter , currently being studied for the treatment of ventricular tachycardia (VT), a leading cause of sudden cardiac death worldwide.
  • In addition, Thermedicals ablation system with degassed saline reduces air bubble volume generated during VT ablation by greater than 98%.
  • In total, there have been 21 patients treated with SERF ablation in Canada, and five treatments also included degassed saline.
  • The Saline Enhanced Radiofrequency (SERF) VT Ablation Early Feasibility Study (EFS) is underway at six centers in the U.S. and Canada.

FDA and Health Canada Approve Thermedical’s Degassed Saline to Help Reduce Risk of Stroke

Tuesday, June 16, 2020 - 2:00pm

Health Canada and the U.S. Food & Drug Administration (FDA) approved Thermedicals degassed saline for use with its Saline Enhanced Radiofrequency (SERF) Ablation system and Durablate catheter , currently being studied for the treatment of ventricular tachycardia (VT), a leading cause of sudden cardiac death worldwide.

Key Points: 
  • Health Canada and the U.S. Food & Drug Administration (FDA) approved Thermedicals degassed saline for use with its Saline Enhanced Radiofrequency (SERF) Ablation system and Durablate catheter , currently being studied for the treatment of ventricular tachycardia (VT), a leading cause of sudden cardiac death worldwide.
  • The reason is that Thermedicals SERF ablation using degassed saline can reach abnormal muscle fibers deep in the heart wall where standard ablation cannot reach and where life-threatening arrhythmias are often located.
  • In addition, Thermedicals ablation system with degassed saline reduces air bubble volume generated during VT ablation by greater than 98%.
  • In total, there have been 21 patients treated with SERF ablation in Canada, and five treatments also included degassed saline.

EHA25Virtual: Combined Irradiation and Chemotherapy Better Prepares Children for Stem Cell Transplantation than Chemotherapy Alone

Friday, June 12, 2020 - 7:30am

More than 90% of ALL patients below 18 years of age are rescued with contemporary chemotherapy.

Key Points: 
  • More than 90% of ALL patients below 18 years of age are rescued with contemporary chemotherapy.
  • One of the most powerful leukemia therapies is hematopoietic stem cell transplantation from a donor (allogeneic HSCT).
  • Reduce the patient's leukemia to an undetectable level with chemotherapy, antibodies, or genetically modified cells from the patient ("CAR-T-cells").
  • For high-risk leukemia, the gold standard conditioning procedure is a combination of total body irradiation (TBI) and high dose chemotherapy.

EHA25Virtual: Combined Irradiation and Chemotherapy Better Prepares Children for Stem Cell Transplantation than Chemotherapy Alone

Friday, June 12, 2020 - 7:30am

More than 90% of ALL patients below 18 years of age are rescued with contemporary chemotherapy.

Key Points: 
  • More than 90% of ALL patients below 18 years of age are rescued with contemporary chemotherapy.
  • One of the most powerful leukemia therapies is hematopoietic stem cell transplantation from a donor (allogeneic HSCT).
  • Reduce the patient's leukemia to an undetectable level with chemotherapy, antibodies, or genetically modified cells from the patient ("CAR-T-cells").
  • For high-risk leukemia, the gold standard conditioning procedure is a combination of total body irradiation (TBI) and high dose chemotherapy.

Enochian BioSciences Announces Its Successful Completion of FDA INTERACT Meeting for a Potential Cure for HIV

Monday, June 8, 2020 - 12:30pm

The meeting, which included management and scientists from Enochian BioSciences together with CBER OTAT staff, focused on the pathway forward for ENOB-HV-01.

Key Points: 
  • The meeting, which included management and scientists from Enochian BioSciences together with CBER OTAT staff, focused on the pathway forward for ENOB-HV-01.
  • ENOB-HV-01 is a novel approach to autologous stem cell transplantation, with the potential to cure HIV by increasing engraftment of gene-modified cells that are resistant to HIV infection.
  • Failure to achieve engraftment has limited the success of other attempts to cure HIV with autologous transplantation.
  • We considered the meeting to be very successful, with strong alignment between Enochians approach to developing ENOB-HV-01 and the comments of the FDA reviewers, said Dr. Mark Dybul, Executive Vice-Chair of Enochian BioSciences.